Posts in Jonathan Gertler Posts
Mentoring the Next Generation of Life Science Innovators
Back Bay Report on Neoantigen-Based Cancer Immunotherapy
Blog, Jonathan Gertler Posts, Michelle Hoffmann Posts, Peter Bak Posts, WhitepapersBack Bay Life Science AdvisorsASCO, Cancer, CART-T, immuno-oncology, Neoantigens, Oncology, T Cell, White Paper
Back Bay CEO Selected as Judge for BIO 2018 Start-Up Stadium
Bloomberg Radio Interview: Danish-American Partnering and Life Sciences Development
Back Bay Life Science Advisors to Lead Fireside Chat with Myovant Sciences President & Chief Executive Officer, Lynn Seely at Convergence Forum 2018
Back Bay Celebrates 8 Years and 450 Life Science Assignments
Xconomy: Proxima Aims to Fill CRO Gap for Houston’s Growing Biotech Community
Life Science Leader: Dynamics and Value of Cross-Border Biotech
Fierce CEO: Back Bay Life Science Advisors CEO Helps Healthcare Companies Grow
Back Bay Life Science Advisors to Lead BioNetwork West Partnering Summit October 23-25
Wall Street Journal Pro Venture Capital: Back Bay’s Jonathan Gertler Comments on Biotech IPO Market
Wall Street Journal: Rise of Earnouts Muddies M&A Waters
Precision Medicine and the Age of Collaboration
Boston Business Journal: A Potential Inflection Point for Biogen
Boston Globe: The End of the IPO Drought
Back Bay Life Science Advisors CEO Jonathan Gertler to Moderate Precision Medicine Panel Discussion with John Quackenbush and Geoffrey McDonough
Bloomberg Baystate Business Hour: Precision Medicine
Life Science Leader - Academia Finds New Ways To Partner With Pharma
Acquiror or Acquiree? The Role of M&A "Deal Heat" in Premium Valuations
Xconomy: Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths
